Nephrocare Health Services Ltd

Nephrocare's capital structure is relatively conservative, with a debt-to-equity ratio of 0.44, indicating a balanced approach to financing. The company maintains a current ratio of 1.92, suggesting it has sufficient short-term assets to cover its liabilities. However, its liquidity position is assessed as medium, and it has negative net cash after subtracting total debt, which could pose a risk in the event of a liquidity crunch. In terms of profitability, Nephrocare's return on equity (ROE) is 11.49%, and its return on assets (ROA) is 6.73%. These figures are in line with the industry's preferred metrics, which emphasize efficient use of equity and asset base to generate returns. The company's operating income of INR 951.78 million and net income of INR 670.96 million reflect a healthy margin, although the exact comparison to industry medians is not available in the provided data. Geographically, Nephrocare's revenue is concentrated in India, with no significant international operations disclosed. The company's business is primarily driven by domestic demand for dialysis and related healthcare services. There is no detailed breakdown of revenue by business segment, but the primary source of income is attributed to patient care and treatment services. Looking at the growth trajectory, Nephrocare has demonstrated consistent revenue growth, with a total revenue of INR 7.56 billion in the latest reporting period. While specific growth rates for the current and next fiscal years are not provided, the company's operating cash flow of INR 1.35 billion and free cash flow of INR 397.90 million indicate a strong cash-generating ability. The capital expenditure of INR 997.75 million suggests ongoing investment in infrastructure and operations to support future growth. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. However, the low dilution risk suggests that the company is not expected to issue additional shares in the near term, preserving shareholder value. The dilution potential is further supported by the fact that the number of diluted shares is the same as the basic shares outstanding, indicating no imminent dilution pressure. Recent events and filings do not show any significant changes in the company's operations or financial strategy. The company's focus remains on expanding its dialysis services and improving patient care. Analysts have provided a mean price target of INR 610.00, with a median price target of INR 610.00, reflecting a generally positive outlook. The mean recommendation of 2.00 (on a scale from 1 to 5) indicates a "buy" rating, with two analysts recommending a "buy" and none recommending a "strong buy" or "hold".